Genomic sequencing identifies secondary findings in a cohort of parent study participants

Michelle L. Thompson, PhD1,†, Candice R. Finnila, PhD1,†, Kevin M. Bowling, PhD1, Kyle B. Brothers, MD, PhD2, Matthew B. Neu, BS1,3, Michelle D. Amaral, PhD1, Susan M. Hiatt, PhD1, Kelly M. East, MS, CGC1, David E. Gray, MS1, James M.J. Lawlor, MS1, Whitley V. Kelley, MS, CGC1, Edward J. Lose, MD3, Carla A. Rich, MA2, Shirley Simmons, RN3, Shawn E. Levy, PhD1, Richard M. Myers, PhD1, Gregory S. Barsh, MD, PhD1, E. Martina Bebin, MD, MPA3 and Gregory M. Cooper, PhD1

Purpose: Clinically relevant secondary variants were identified in parents enrolled with a child with developmental delay and intellectual disability.

Methods: Exome/genome sequencing and analysis of 789 "unaffected" parents was performed.

Results: Pathogenic/likely pathogenic variants were identified in 21 genes within 25 individuals (3.2%), with 11 (1.4%) participants harboring variation in a gene defined as clinically actionable by the American College of Medical Genetics and Genomics. These 25 individuals self-reported either relevant clinical diagnoses (5); relevant family history or symptoms (13); or no relevant family history, symptoms, or clinical diagnoses (7). A limited carrier screen was performed yielding 15 variants in 48 (6.1%) parents. Parents were also analyzed as mate pairs (n = 365) to identify cases in which both parents were carriers for the same recessive disease, yielding three such cases (0.8%), two of which had children with the relevant recessive disease. Four participants had two findings (one carrier and one noncarrier variant). In total, 71 of the 789 enrolled parents (9.0%) received secondary findings.

Conclusion: We provide an overview of the rates and types of clinically relevant secondary findings, which may be useful in the design and implementation of research and clinical sequencing efforts to identify such findings.

Genet Med advance online publication 12 April 2018

Key Words: ACMG; Clinical Sequencing Exploratory Research Consortium; disease risk; genomic sequencing; secondary findings

INTRODUCTION

Whole-exome and whole-genome sequencing have proven to be powerful tests for identifying clinically relevant genetic variation. The existence of secondary and incidental findings has catalyzed debate regarding the types of findings that should be sought by sequencing labs, the circumstances in which certain types of variants should be returned, and the necessary extent of patient consent, education, and genetic counseling. The American College of Medical Genetics and Genomics (ACMG) released recommendations about the interpretation of variants in genes considered to be clinically actionable, including those that confer a high risk of cancer or heart disease. The ACMG recommends that these be sought and provided to patients that consent to receive such results.1,2 Recommendations related to use of specific gene lists and approaches for returning secondary findings were intended to be used in clinical contexts, although it is also important to examine them in translational research contexts.

Through a study that was part of the Clinical Sequencing Exploratory Research (CSER) Consortium,3 we assessed the utility of whole-exome/whole-genome sequencing to identify genetic causes of developmental delay, intellectual disability (DD/ID), and related congenital anomalies. We have sequenced affected probands from 455 families, and have identified DD/ID-related pathogenic/likely pathogenic (P/LP) variants in 29% of cases.4 As our DD/ID study includes proband–parent trios, we have the ability to assess secondary findings in a sizable cohort of adults.3

We use the term “secondary findings” throughout this work to describe variation identified via proactive searching5 and report rates and types of secondary findings in context of reported symptoms or family history. Our experiences and data suggest the value of genomic sequencing in a clinical setting not only for disease patients, but also for those not currently exhibiting an overt disease phenotype. We demonstrate the utility of dissemination of such findings in a cohort of parent study participants, and highlight this through case-study analyses.

1HudsonAlpha Institute for Biotechnology, Huntsville, Alabama, USA; 2University of Louisville, Department of Pediatrics, Louisville, Kentucky, USA; 3University of Alabama at Birmingham, Birmingham, Alabama, USA. Correspondence: Gregory M. Cooper (gcooper@hudsonalpha.org)

†The first two authors contributed equally to this work.

Submitted 31 August 2017; accepted 6 March 2018; advance online publication 12 April 2018. doi:10.1038/gim.2018.53
**MATERIALS AND METHODS**

**Study participant population**
There was no public recruitment for this study. Parent and child ($n = 455$ families) participants were enrolled at North Alabama Children’s Specialists in Huntsville, AL. Consent was obtained for study participation and publication of data generated by this study. Review boards at Western Institutional Review Board (20130675) and the University of Alabama at Birmingham (X130201001) approved and monitored this study.

**Patient preferences and consent**
We developed the Preferences Instrument for Genomic Secondary Results to elicit parents’ preferences for receiving categories of secondary results. This instrument divides secondary findings into 13 disease categories (Figure 1). Results were returned only to participants who opted to receive secondary findings. Decisions regarding disclosure of secondary findings solely in the proband were based on a combination of parent preferences for themselves and medical relevance to the proband during childhood. In the case of adopted probands, preferences were solicited from the adoptive parents on behalf of the proband.

**Phenotyping**
At enrollment, a genetic counselor generated a three-generation pedigree based on information provided by the parents/guardians of the proband. Parents’ health records were not available to the study nor was a physical exam performed. The genetic counselor asked questions related to family history of cancer and sudden/unusual deaths of adults (e.g., cardiac arrest). Cascade sequencing was not conducted as part of this study. We have (i) retained the language used by the participant to describe their phenotypes or family histories and (ii) included any reported information that is plausibly related to the phenotype of concern.

**Return of results**
Participants who received secondary findings were scheduled for private disclosure with a medical geneticist and genetic counselor. The clinical significance of findings was addressed and documents detailing variant information and relevant resources were provided. Secondary findings were not by default placed in the participant’s medical record and no formal referrals to relevant specialists were made. If the participants chose to share results with their health-care provider, formal referrals were coordinated.

**Sequencing and variant information**
Further details regarding whole-exome/whole genome sequencing, read alignment, variant calling, filtering, classification, and validation can be found in our previous report and in the Supplementary Methods online. Briefly, we searched for: P/LP variation in ACMG genes; P/LP variation in ClinVar outside of ACMG genes; recessive variation in individuals who harbored two or more P/LP variants in the same gene; variation in which both parents of a pair harbored P/LP variation for the same recessive disorder (defined in OMIM); and carrier status information in CFTR, HEXA, and HBB. Only P/LP variants were returned.

**Data sharing**
Identified variants in parent participants have been shared through ClinVar and dbGaP, with consent. Additional information is provided in the Supplementary Methods online.

**RESULTS**

**Demographics of study population**
Of 455 enrolled families, 424 included at least one parent, and both parents were available for 365 families. Demographics...
for the 789 parent participants are reported in Table 1. The study population had a mean age of 41 years and included 422 females and 367 males; 80.5% self-reported to be of European ancestry ("White"), 8.5% as African American ("Black"), and 8.2% as "Other or Multiracial." More than 25% had a high school diploma or less, and 34.5% reported some college education (Table 1).

### Table 1 Demographics of parent participants enrolled in the HudsonAlpha Clinical Sequencing Exploratory Research Consortium project

|                                | Total, mean (SD) (n = 789) | Males, mean (SD) (n = 367) | Females, mean (SD) (n = 422) |
|--------------------------------|-----------------------------|-----------------------------|-----------------------------|
| **Age**                        | 40.95 (9.4)                 | 42.63 (9.67)                | 39.49 (8.94)                |
| **Race**                       |                             |                             |                             |
| White                          | 635 (80.5%)                 | 295 (80.4%)                 | 340 (80.6%)                 |
| Black or African American      | 67 (8.5%)                   | 28 (7.6%)                   | 39 (9.2%)                   |
| American Indian/Alaska Native  | 7 (0.9%)                    | 6 (1.6%)                    | 1 (0.2%)                    |
| Other/multiracial              | 65 (8.2%)                   | 30 (8.2%)                   | 35 (8.3%)                   |
| No answer                      | 15 (1.9%)                   | 8 (2.2%)                    | 7 (1.7%)                    |
| **Ethnicity**                  |                             |                             |                             |
| Hispanic or Latino             | 32 (4.0%)                   | 16 (4.4%)                   | 16 (3.8%)                   |
| Not Hispanic or Latino         | 750 (95.1%)                 | 349 (95.1%)                 | 401 (95.0%)                 |
| No answer                      | 7 (0.9%)                    | 2 (0.5%)                    | 5 (1.2%)                    |
| **Education**                  |                             |                             |                             |
| Less than high school diploma  | 79 (10.0%)                  | 44 (12.0%)                  | 35 (8.3%)                   |
| High school Diploma/GED        | 122 (15.4%)                 | 67 (18.2%)                  | 55 (13.0%)                  |
| Some college                   | 272 (34.5%)                 | 113 (30.8%)                 | 159 (37.7%)                 |
| Bachelor’s degree              | 197 (25.0%)                 | 84 (22.9%)                  | 113 (26.8%)                 |
| Graduate degree                | 118 (15.0%)                 | 58 (15.8%)                  | 60 (14.2%)                  |
| No answer                      | 1 (0.1%)                    | 1 (0.3%)                    | 0 (0.0%)                    |

Race, ethnicity, education are self-reported.

### Table 2 Unique variants of carrier status in CFTR, HEXA, and HBB

| Unique variant info | No. of individuals |
|---------------------|--------------------|
| **CFTR (MIM 219700)** | 4.4% of total population |
| F508del             | 22                 |
| G685fs              | 3                  |
| D1152H              | 2                  |
| G551D               | 2                  |
| G542*               | 2                  |
| R117H               | 2                  |
| c.489+1G>T          | 1                  |
| F342Hfs             | 1                  |
| **HEXA (MIM 272800)** | 0.6% of total population |
| Y427Ils             | 2                  |
| c.986+3A>G          | 1                  |
| c.459+5G>A          | 1                  |
| c.1073+1G>A         | 1                  |
| **HBB (MIM 603903; 613985)** | 1% of total population |
| E7V                 | 6                  |
| E27K                | 1                  |
| G40*                | 1                  |

### Patient preferences

One goal of our study was to understand preferences as they relate to receiving secondary findings across various disease categories. Eighty-five percent of parents requested all secondary findings, while 1.6% declined to receive all findings. The most frequently requested category was risk for gender-specific cancers (breast, ovarian, testicular, and prostate; n = 584, 96.1%). The least frequently requested result was risk for developing obesity (n = 542, 89.2%) (Figure 1).

### Carrier status findings

We conducted a limited carrier screen for variants relevant to cystic fibrosis (CFTR, MIM 219700), β-thalassemia (HBB, MIM 613985), sickle cell disease (HBB, MIM 603903), and Tay–Sachs disease (HEXA, MIM 272800), which are among the most common Mendelian diseases (average carrier risk is 1/40) (refs. 7–9). We observed eight P/LP variants in CFTR across 35 individuals (4.4% of parent cohort), four HEXA variants across five individuals (0.6%), and three HBB variants across eight individuals (1%) (Table 2; Supplementary Table S2 online). Additionally, we searched for cases in which parental "mate pairs" were both carriers for variants in a gene associated with a recessive disorder that was not relevant to the proband’s developmental disability (i.e., was truly "secondary" relative to the reason for study enrollment). This analysis led to three returnable results, including a parent pair with recessive mutations in each of OCA2 (MIM 203200), FYCO1 (MIM 610019), and ATP7B (MIM 277900) (Supplementary Table S2 online). For the former two cases (OCA2 and FYCO1), the enrolled probands inherited both alleles and were affected by the given disease (see below),
while the latter family (ATP7B) did not have any currently affected children.

**Secondary variants in individuals reporting a relevant clinical diagnosis**

P/LP variants were found in five individuals with a self-reported previous clinical diagnosis but in whom a specific genetic cause was unknown. A 35-year-old woman was found to harbor a heterozygous missense variant in SLC4A1 (spherocytosis, MIM 612653), and had family history of related disease (Table 3; Supplementary Table S1 online). We identified three missense variants (two likely in cis) in SLC22A5 in a 37-year-old woman with recessive systemic primary carnitine deficiency (MIM 212140). Finally, a canonical splice donor site (D1) variant affecting PKD2 was identified in a 36-year-old woman with polycystic kidney disease (MIM 613095). This individual also reported a family history of disease (Table 3; Supplementary Table S1 online).

Secondary genetic variation related to cardiovascular disease was identified in two individuals with a previous clinical diagnosis and a family history of cardiovascular phenotypes. One 30-year-old woman reported to have experienced cardiomyopathy postpartum, had a paternal family history of arrhythmia, and stated that her paternal uncle suffered two “heart attacks” prior to age 40. She was found to harbor a frameshift variant in DSG2, a gene associated with arrhythmogenic right ventricular dysplasia and dilated cardiomyopathy (MIM 610193, MIM 612877). Although DSG2 has not per se been associated with peripartum cardiomyopathy, we find it probable that the variant explains her disease history. The clinical symptoms of peripartum cardiomyopathy are similar to those of dilated cardiomyopathy, and other genetic variants associated with dilated cardiomyopathy are thought to be risk factors for peripartum cardiomyopathy.* In a 52-year-old man with hypertrophic cardiomyopathy and arrhythmia, we identified missense variation in ANK2, a gene associated with ankyrin-B-related cardiac arrhythmia and long QT syndrome (MIM 600919). It is unknown whether this individual presents with long QT intervals. Additionally, although not clearly related to ANK2 variation, this individual also reported that his father had ischemic heart disease.

Finally, six of the eight parents carrying P/LP variation in HBB reported having sickle cell or thalassemia trait at time of enrollment (Table 2; Supplementary Table S2 online).

**Secondary variants in individuals reporting relevant symptoms and/or family history**

We identified secondary variants in 13 individuals with no previous diagnosis or genetic testing despite the manifestation of disease and/or family history (Table 3; Supplementary Table S1 online). Given information provided at time of enrollment, six of these cases (CLCN1, MFN2, BRCA1, BRCA2, BARD1, and PMS2; Table 3) would have met criteria for genetic consultation and testing via standard clinical guidelines.12,13 Given additional phenotypic information acquired at return of results, two additional cases (SCN4A and HARS; Table 3) would have met such criteria.14,15 These eight cases are described below.

A heterozygous missense variant in CLCN1 was identified in a 29-year-old woman who reported leg cramps and restless legs beginning in childhood. Variation in CLCN1 associates with myotonia congenita (MIM 160800) characterized by muscle stiffness. Her mother was diagnosed with myotonia congenita when she was 10 years old, and her maternal grandfather had a muscle biopsy performed in his 30s due to presentation of symptoms, including “stiffness” that occurred “especially in cold [temperatures].” In a separate case, a heterozygous missense variant in MFN2 (Charcot–Marie–Tooth disease type 2A2A, MIM 609260) was identified in a 35-year-old woman who reported balance difficulties and weakness since childhood that have progressed to severe cramping, myalgia, and numbness most prominently in lower extremities. Her family history is notable for neuromuscular disorder, with similar symptoms present in her brother, father, paternal grandmother, and paternal aunt. Though a clinician has not formally evaluated her, she reported that her brother was diagnosed with Charcot–Marie–Tooth.

We also identified cancer risk variants in individuals who report a family history of cancer. We identified a frameshift variant in BRCA1 (familial breast/ovarian cancer, MIM 604370) in a 40-year-old man whose mother was diagnosed with breast cancer in her 30s. In another case, a canonical splice acceptor variant of BRCA2 (familial breast/ovarian cancer, MIM 612555) was identified in a 38-year-old woman who had a history of breast cancer on both sides of the family: paternal grandmother (unknown age) and maternal grandfather (age 60). A frameshift variant in BARD1 (Breast cancer, MIM 114480) was identified in a 33-year-old woman whose maternal grandmother had bladder, lung, and peritoneal cancer as well as a great-grandmother diagnosed with breast cancer in her 50s. Additionally, a frameshift variant in PMS2 (hereditary nonpolyposis colorectal cancer; MIM 614337) was identified in a 43-year-old man with a family history of colon cancer—father (60s) and paternal aunt (40s). This individual also had a paternal aunt and grandmother who were diagnosed with breast cancer in their 60s and 50s, respectively. After receipt of this finding, the study participant followed up with a colonoscopy, the results of which were negative. He reports that he will continue periodic assessment.

Secondary variants were also identified in two symptomatic individuals who were not aware that their symptoms were unusual and thus never had clinical or genetic evaluation (Table 3). At enrollment, neither individual reported relevant phenotypes to the variants identified. In one case, a 28-year-old woman was found to harbor a pathogenic missense variant in SCN4A, implicated in hyperkalemic periodic paralysis and paramyotonia congenita (MIM 170500, 168300), neuromuscular disorders characterized by intermittent muscle weakness and/or myotonia. At results return, she reported a history of painful stiffness during exercise that began at approximately age 5 and that her throat “locks up”
**Table 3** Secondary findings of enrolled parents segregated into “Relevant clinical diagnoses”, “Relevant family history or symptoms”, and “No relevant family history, symptoms or clinical diagnosis”

| Age (M/F) | Gene | Variant info | Associated phenotype (MIM) | Phenotypes or family history reported by parent participants |
|-----------|------|--------------|----------------------------|-----------------------------------------------------------|
| **Relevant clinical diagnoses reported (0.6% total population)** | | | | |
| 35 (F) | SLC4A1 | V488M | Spherocytosis, type 4 (612653) | Clinically diagnosed with spherocytosis; two daughters and father with spherocytosis |
| 37 (F) | SLC22A5 | A142S; T440M, R488H | Carnitine deficiency, systemic primary (212140) | Clinically diagnosed with carnitine deficiency |
| 36 (F) | PKD2 | c.1319+1G>A | Polycystic kidney disease 2 (613095) | Clinically diagnosed with polycystic kidney disease; mother, brother, two nieces, maternal aunt, uncle, and grandmother with polycystic kidney disease |
| 30 (F) | DSG2 | V986fs | Cardiomyopathy, dilated, 1BB; arrhythmogenic right ventricular dysplasia 10 (612877; 610193) | Clinically diagnosed with postpartum cardiomyopathy; paternal family history of arrhythmia; paternal uncle with two “heart attacks” prior to age 40 |
| 52 (M) | ANK2 | E1458G | Cardiac arrhythmia, ankyrin-B-related, long QT syndrome 4 (600919) | Clinically diagnosed with hypertrophic cardiomyopathy and arrhythmia; father died with ischemic heart disease |
| **Relevant family history or symptoms reported (1.6% of total population)** | | | | |
| 29 (F) | CLCN1 | F413C | Myotonia congenita, dominant (160800) | Leg cramps and restless legs in childhood, still occasionally has cramps; Mother diagnosed with myotonia congenita, 10 years; Maternal grandfather with a muscle biopsy performed in 30s and “stiffness” especially in cold |
| 35 (F) | MFN2 | W740S | Charcot–Marie–Tooth disease, axonal, type 2A2A (609260) | History of muscle wasting in back, lower extremities; brother clinically diagnosed with Charcot–Marie–Tooth, 30s; multiple family members affected with “unspecified muscle disorder” |
| 40 (M) | BRCA1 | G1756fs | Breast/ovarian cancer, familial 1 (604370) | Mother with breast cancer, 30s |
| 38 (F) | BRCA2 | c.8488-1G>A | Breast/ovarian cancer, familial 2 (612555) | Maternal grandmother with bilateral breast cancer, 60s; paternal grandmother with breast cancer, age unknown |
| 33 (F) | BARD1 | E652fs | Breast cancer susceptibility (114480) | Maternal great-grandmother with breast cancer, 50s; Maternal grandmother had bladder, lung, and peritoneal cancer, age unknown |
| 43 (M) | PMS2 | P246fs | Hereditary nonpolyposis colorectal cancer, type 4 (614337) | Father (60s) and paternal aunt (40s) had colon cancer; paternal aunt (60s) and grandmother (50s) with breast cancer |
| 28 (F) | SCN4A | T1313M | Paramyotonia congenita (168300) | At enrollment, no report of neuromuscular phenotypes. At return of results, indicated that she had muscle stiffness but always thought she was “easily fatigued” and had “low stamina”; mother displays similar symptoms |
| 41 (M) | HARS | R137Q | Charcot–Marie–Tooth, axonal, type 2W (616625) | At enrollment, no report of neuromuscular phenotypes. At return of results, indicated that he had Charcot–Marie–Tooth associated phenotypes. Always thought he was “just clumsy” |
| 32 (F) | KCNQ1 | R366W | Long QT syndrome 1 (192500) | Father with coronary artery disease with triple bypass, early 50s; paternal aunt with early-onset stroke, late 30s |
| 47 (M) | KCNQ1 | P7S | Long QT syndrome 1 (192500) | Mother “fainted” and “hit the floor”; was told this impact prevented cardiac arrest |
| 39 (M) | MYBPC3 | E542Q | Hypertrophic cardiomyopathy 4; dilated cardiomyopathy 1MM (115197; 615396) | “Leaky heart valve”; Dad has pacemaker and mom has “leaky heart valve,” 60s |
| 30 (M) | DDX41 | D140fs | Susceptibility to familial myeloproliferative/lymphoproliferative neoplasms (616871) | Paternal cousin with lymphoma “unspecified,” age unknown |
| 37 (F) | MC4R | C271Y | Obesity, autosomal dominant (601665) | Obese (body mass index: 41) |
after drinking cold liquids. Additionally, she reported that her eyelids “stick” and “become heavy” throughout the day. She noted that her mother displays similar phenotypes. This individual plans to follow up with a neurologist. In a second case, a 41-year-old man was found to harbor pathogenic variation in HARS, associated with Charcot–Marie–Tooth disease Type 2W (MIM 616625) characterized by gait difficulties and sensory impairment caused by peripheral neuropathy. At return of results, he indicated that he was “clumsy,” was discharged from military boot camp due to his inability to march in formation, and often wears out shoes because he shuffles his feet.

Secondary variants in individuals reporting no relevant symptoms or family history of disease

We also identified P/LP variants in individuals that are currently asymptomatic and report no relevant family history (Table 3). Two unrelated individuals, a 52-year-old woman and a 50-year-old man, were found to harbor variation in SCN5A (long QT syndrome, MIM 603830) and DSG2 (dilated cardiomyopathy, MIM 612877), respectively. A 31-year-old man was found to harbor a missense variant in ACTN1, associated with a bleeding disorder (MIM 615193). Finally, P/LP cancer-associated variants were identified in four participants with no personal or family history, including one in each of MSH2, BARD1, BRCA2, and RET (Table 3; Supplementary Table S1 online). Notably, a pathogenic missense variant (C609Y) in RET, associated with multiple endocrine neoplasia type 2A (MIM 171400), medullary thyroid carcinoma (MTC; MIM 155240), and/or Hirschsprung disease (MIM 142623), was identified in a 52-year-old man who reported no history of RET-associated cancer. C609Y has been observed in many medullary thyroid carcinoma–affected individuals and indicates level B risk according to the American Thyroid Association (D is the highest risk level), with an expected age of onset of less than 30 years. Recommendations for C609Y carriers vary but often include prophylactic thyroidectomy at a young age. However, more recent studies indicate RET C609Y may have lower penetrance or later onset of medullary thyroid carcinoma than previously noted, consistent with the observation of no related cancers in this family. Interestingly, while C609Y was not transmitted to the enrolled, developmentally delayed proband, the family reported that they have another daughter who has Hirschsprung disease and is therefore likely to have inherited C609Y. The family was referred for genetic counseling to test for the variant in the Hirschsprung-affected daughter and it was recommended that both the father and daughter follow up with oncologists.

Secondary findings in DD/DD-affected children

For three enrolled children, we identified secondary variation not inherited from a parent. Two individuals whose biological parents were not available harbored pathogenic variation in CFTR (Phe508del) and BRCA2 (Leu579*), respectively. Also, a
6-year-old girl harbored a pathogenic de novo variant in FBN1 (Asn2144Ser). At time of analysis, this proband did not exhibit Marfan phenotypes (MIM 154700), with exception of crowded teeth and scoliosis. In three additional probands, compound heterozygous variation associated with recessive disease was identified. Two P/LP variants, one inherited from each carrier parent, in OCA2 (oculocutaneous albinism type II, MIM 203200) were identified in an 11-year-old boy and his 6-year-old brother; both presented with albinism. In a third case, a 9-year-old girl with cataracts was found to have inherited a P/LP variant from each carrier parent in FYCO1, a gene associated with cataract 18 (MIM 610019).

**DISCUSSION**

The ACMG estimated that secondary findings in genes relevant to a defined list of actionable phenotypes would be found in ~1% of sequenced individuals.1,2 We observed variation in ACMG-defined genes in 1.4% of parent participants, consistent with that estimate and the 1–5.6% reported by other laboratories.22–25

Our study assessed carrier status in all participants for only three genes—HBB, HEXA, and CFTR—leading to the identification of P/LP variation in ~6.1% of parent participants. These genes were selected based on their anticipated frequencies in the population sampled and our desire to balance yield with analytical and cost burden. Had we assessed all genes known to associate with recessive disease,26 the burden of analysis would have increased substantially.27,28

Further, expanded carrier screening and discovery efforts would have increased Sanger validation costs and the time required from genetic counselors and medical geneticists for return of results. Thus, while our choice of genes as targets for carrier analysis was semiarbitrary, it imposed minimal analytical burden and led to a substantial but manageable yield relevant to a few of the most prevalent Mendelian diseases.

One additional more comprehensive carrier status strategy we used was to search within both parents of a parental pair for P/LP variants in the same gene (expanding beyond CFTR, HBB, and HEXA to include all genes associated with recessive disease in OMIM). Of the 365 parental pairs enrolled, recessive disease risk (i.e., 25% for their children) was identified in three (0.8% of parental pairs). This rate is likely to grow in the future as additional evidence accrues on the pathogenicity of variants in genes causing recessive disorders.22 The treatment of parental pairs as units of analysis for carrier status is an effective way to minimize analytical and cost burden and yet effectively capture those carrier results likely to have the greatest potential impact.

Copy-number variation (CNV) was not explored in parents as a source of secondary findings. This decision was driven by the considerable manual scrutiny that is required to evaluate the technical quality of CNVs, the costs and challenges of CNV validation, and the relative lack of robust CNV population frequency data, particularly for smaller events. Analyses of CNVs as secondary variation may be of interest to future efforts to increase the yield of medically relevant information from sequencing data.

**Patient preferences**

The question of whether patients and research participants need to be offered choices about receiving secondary findings has been debated, especially after the release of ACMG’s original secondary findings recommendations in 2013.1 Studies have documented that most participants want most—and usually all—possible secondary findings. This trend is consistent between studies asking this question as a hypothetical29–33 or to inform actual return of results.34–37 Consistent with these previous studies, the vast majority (84.8%) of parents participating in our study chose to receive all categories of secondary results. However, a minor but substantial fraction of participants (15.2%) declined at least one category and 1.6% declined all secondary results. One of the secondary findings listed in Table 3 was not returned because the parent had declined the relevant category.

**Challenges associated with variant interpretation**

One of the most challenging tasks when analyzing secondary findings is interpretation of genetic variation, particularly for variants that have not been previously described in scientific literature or in clinical genetic databases. Even variants previously reported to be pathogenic are often supported only by weak evidence or conversely associated with strong evidence for being benign.38 Interpretation is made even more challenging when an individual harbors potential disease-associated variation but does not present with the associated phenotype or have a family history of disease. That said, in this study, ACMG evidence codes were assigned and variants that were deemed to be P/LP were offered for return regardless of the presence or absence of any particular phenotype or family history. Even for those with indications of disease, the particular phenotypes reported (Table 3) are not necessarily directly related to the presence of the given variant. Imprecision and incompleteness of self-reported diseases and family histories and limitations to knowledge of penetrance and expressivity for any given gene, and especially any given variant, all make interpretation more challenging. More precise phenotyping and partnership with referring physicians would be beneficial for laboratories attempting to interpret identified variants.

**Utility of secondary findings**

The secondary genetic findings that we identified may be of considerable utility to the parent participants. For five individuals, we were able to confirm, and genetically explain, a previous clinical diagnosis (Table 3). Such information may prove useful for future clinical management and in discussions with family members that may carry the same variant. Secondary genetic findings were also identified in 13 individuals who reported family history or symptoms that are likely to associate with the detected variant. As described in the results section, genetic counseling and testing could/
should have been offered in eight cases based solely on observed symptoms and/or family history. Additionally, we identified secondary genetic variants in four individuals who have an increased risk of disease with modest but nontrivial evidence for disease (two cases of KCNQ1; one case each of MYBPC3 and DDX41). Through participation in our study, these individuals now have a better understanding of their cause or risk of disease and are in position to better manage that disease or risk of disease.

We also identified secondary genetic variation in seven individuals who report neither symptoms nor family history of disease (MSH2, RET, BARD1, BRCA2, ACTN1, SCN5A, and DSG2). These study participants appear to be at increased risk of disease and it has been suggested that they follow up with an appropriate specialist (Table 3) in the hopes that actions can be taken to screen for, prevent, or mitigate unobserved disease in these individuals.

Finally, we also identified secondary variation in DD/ID affected probands that were not identified in parents, either due to unavailability of parents (n = 2) or as a result of the variant arising de novo (n = 1). Further, three children from two families were found to harbor compound heterozygous variation relevant to an observed disease that was unrelated to their developmental disabilities (i.e., albinism and cataracts).

Challenges of returning unexpected variants to families
Many parents in this study have experienced a diagnostic odyssey in hopes of identifying the cause of their child’s developmental disabilities. Individuals who carried P/LP secondary variants therefore required counseling and recommendations for clinical follow-up regarding their secondary findings, in addition to information regarding the care and well-being of their affected children. Returning genetic information relevant to a new or unexpected disease risk may be particularly problematic when no results are found relevant to the primary indication for testing. In our study, 51% of the secondary findings identified in the parents were transmitted to the DD/ID-affected proband, and 56% of the 71 parents who harbored a secondary finding did not receive a primary result for their enrolled DD/ID-affected child. The lack of a primary result may increase the shock value of a secondary finding. A parent may expect the conversation to revolve around their child’s health but instead spends time discussing the meaning of their own disease risk and/or an additional, unexpected disease risk relevant to their already affected child. This fact highlights the potential financial, emotional, and clinical implications of secondary findings that should be clearly addressed in the informed consent discussion prior to sequencing so that families are aware of all the possible outcomes of this type of testing.

Conclusions
Our study describes the identification and return of secondary variation to parents who were subject to genomic sequencing for diagnosis of a developmentally delayed child. Although the return of secondary genetic variation has been debated, a large majority of parent participants in this study opted to receive all identified secondary findings, regardless of disease category, suggesting that participants are generally open to receiving genetic information that may be relevant to their health. This study demonstrates the utility of returning secondary variants, as it may facilitate preventive screening for individuals who are genetically predisposed to serious diseases. This information can also be useful to individuals who have been clinically diagnosed with a condition but for which a specific causal explanation is unknown. We have also shown that secondary genetic information may lead to clinical diagnosis in individuals who have experienced symptoms related to a disorder not previously diagnosed. Some individuals also described significant family history that would have justified, but did not lead to, genetic evaluation independent of their participation in this study. Finally, our study describes a framework for identifying secondary genetic variation in a broad yet manageable manner, including a limited but productive carrier screen on only a few common Mendelian diseases along with a more comprehensive screen treating parents as mate pairs. The methods and results related to secondary variation identification may be of use to other research and clinical laboratories that are conducting genomic sequencing.

SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http://www.nature.com/gim

ACKNOWLEDGMENTS
This work was supported by grants from the US National Human Genome Research Institute (UM1HG007301). We are grateful to the families who contributed to this study. We thank the staff at North Alabama Children’s Specialists (Children’s of Alabama in Huntsville, AL), the HudsonAlpha Software Development and Informatics team, the Genomic Services Laboratory at HudsonAlpha, and the HudsonAlpha Clinical Services Lab who contributed to data acquisition and analysis.

DISCLOSURE
The authors declare no conflict of interest.

REFERENCES
1. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013;15:565–574.
2. Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med 2017;19:249–255.
3. Green RC, Goddard KA, Janvik GP, et al. Clinical Sequencing Exploratory Research Consortium: accelerating evidence-based practice of genomic medicine. Am J Hum Genet 2016;98:1051–1066.
4. Bowling KM, Thompson ML, Amaral MD, et al. Genomic diagnosis for children with intellectual disability and/or developmental delay. Genome Med 2017;9:43.
5. Weiner C. Anticipate and communicate: ethical management of incidental and secondary findings in the clinical, research, and direct-to-consumer contexts (December 2013 report of the Presidential Commission for the Study of Bioethical Issues). Am J Epidemiol 2014;180:562–564.
6. Brothers KB, East KM, Kelley WV, et al. Eliciting preferences on secondary findings: the Preferences Instrument for Genomic Secondary Results. *Genet Med* 2017;19:337–344.

7. Zvereff VV, Faruki H, Edwards M & Friedman KJ. Cystic fibrosis carrier screening in a North American population. *Genet Med* 2014;16:539–546.

8. Branda KJ, Tomczak J & Natowicz MR. Heterozygosity for Tay-Sachs and Sandhoff diseases in non-Jewish Americans with ancestry from Ireland, Great Britain, or Italy. *Genet Test* 2004;8:174–180.

9. Modell B, Darlison M, Birgins H, et al. Epidemiology of haemoglobin disorders in Europe: an overview. *Scand J Clin Lab Invest* 2007;67:39–69.

10. Bollen IA, Van Deel ED, Kuster DW & Van Der Velden J. Peripartum cardiomyopathy and a dilated cardiomyopathy: different at heart. *Front Physiol* 2014;5:531.

11. Morales A, Painter T, Li R, et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. *Circulation* 2010;121:2176–2182.

12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast and Ovarian. V.2.2017. Accessed 20 August 2017. https://www.nccn.org/professionals/physician_gls/default.aspx.

13. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colorectal. V.2.2017. Accessed 20 August 2017. https://www.nccn.org/professionals/physician_gls/default.aspx.

14. Bird TD. Charcot-Marie-Tooth hereditary neuropathy overview. In: Pagon RA, Bird TD, Dolan CR, Stephens K (eds). *GeneReviews*. University of Washington: Seattle, WA, 1993.

15. Duno M & Colding-Jorgensen E. Myotonia congenita. In: Pagon RA, Bird TD, Dolan CR, Stephens K (eds). *GeneReviews*. University of Washington: Seattle, WA, 1993.

16. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. *Thyroid* 2009;19:565–612.

17. de Groot JW, Sijmons RH, Links TP, Plukker JT & Hofstra RM. Medullary thyroid cancer in a patient with Hirschsprung disease with a C609Y germline RET-mutation. *J Pediatr Gastroenterol Nutr* 2005;40:226–229.

18. Marguard J & Eng C. Multiple endocrine neoplasia type 2. In: Pagon RA, Bird TD, Dolan CR, Stephens K (eds). *GeneReviews*. University of Washington: Seattle, WA, 1993.

19. Calva D, O’Dorriso TM, Sue O’Dorriso M, et al. When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation? *Ann Surg Oncol* 2009;16:2237–2244.

20. Speak R, Cook J, Harrison B & Newell-Price J. Disease-modifying polymorphisms and C609Y mutation of RET associated with high penetrance of phaeochromocytoma and low rate of MTC in MEN2A. *Endocrinol Diabetes Metab Case Rep* 2016;2016:0093.

21. Rich TA, Feng L, Busaidy N, et al. Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations. *Thyroid* 2014;24:1096–1106.

22. Gambin T, Jhangiani SN, Below JE, et al. Secondary findings and carrier test frequencies in a large multiracial sample. *Genome Med* 2015;7:54.

23. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015;17:405–424.

24. Dorschner MO, Amendola LM, Turner EH, et al. Actionable, pathogenic incidental findings in 1,000 participants’ exomes. *Am J Hum Genet* 2013;93:631–640.

25. Amendola LM, Dorschner MO, Robertson PD, et al. Actionable exonic incidental findings in 6503 participants: challenges of variant classification. *Genome Res* 2015;25:305–315.

26. Hamosh A, Scott AF, Amberger JS, Bocchini CA & McKusick VA. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. *Nucleic Acids Res* 2005;33(database issue):D514–517.

27. Berg JS, Adams M, Nassar N, et al. An informatics approach to analyzing the incidentalome. *Genet Med* 2013;15:36–44.

28. Talbot HK, Auer PL, Jamal SM, et al. Pathogenic variants for Mendelian and complex traits in exomes of 6,517 European and African Americans: implications for the return of incidental results. *Am J Hum Genet* 2014;95:183–193.

29. Graves KD, Sinicrope PS, McCormick JB, Zhou Y, Vadaparampil ST & Lindor NM. Public perceptions of disease severity but not actionability correlate with interest in receiving genomic results: nonalignment with current trends in practice. *Public Health Genomics* 2015;18:173–183.

30. Driessnack M, Daack-Hirsch S, Downing N, et al. The disclosure of incidental genomic findings: an “ethically important moment” in pediatric research and practice. *J Community Genet* 2013;4:435–444.

31. Yu JH, Crouch J, Jamal SM, et al. Patient decisions for disclosure of secondary findings among the first 200 individuals undergoing clinical diagnostic exome sequencing. *Genet Med* 2014;16:395–399.

32. Kaphingst KA, Ivanovich J, Biesecker BB, et al. Preferences for return of incidental findings from genome sequencing among women diagnosed with breast cancer at a young age. *Clin Genet* 2016;89:378–384.

33. Wynn J, Martinez J, Duong J, et al. Research participants’ preferences for hypothetical secondary results from genomic research. *J Genet Couns* 2017;26:841–851.

34. Shahmirzadi L, Chao EC, Palmaer E, Parra MC, Tang S & Gonzalez KD. Patient decisions for disclosure of secondary findings among the first 200 individuals undergoing clinical diagnostic exome sequencing. *Genet Med* 2016;14:395–399.

35. Sanderson SC, Linderman MD, Suckiel SA, et al. Motivations, concerns and preferences of personal genome sequencing research participants: baseline findings from the HealthSeq project. *Eur J Hum Genet* 2016;24:153.

36. Louie JT, Bremer RC, Mai PL, et al. Research participant interest in primary, secondary, and incidental genomic findings. *Genet Med* 2016;18:1218–1225.

37. Bishop CL, Strong KA & Dimmock DP. Choices of incidental findings of individuals undergoing genome wide sequencing, a single center’s experience. *Clin Genet* 2017;91:137–140.

38. MacArthur DG, Manolio TA, Dimmock DP, et al. Guidelines for investigating causality of sequence variants in human disease. *Nature* 2014;508:469–476.

39. Wolf SM, Annas GJ & Elias S. Point-counterpoint. Patient autonomy and incidental findings in clinical genomics. *Science* 2013;340:1049–1050.

40. Biesecker LG. Incidental variants are critical for genomics. *Am J Hum Genet* 2013;92:648–651.